Damora Therapeutics, Inc. Insider Trading

DMRA

Last 12 months

Insiders bought 253K and sold 31K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Executive Officer Hans T. Schambye sold 15K on Jan 2, 13% of their stake, outside a plan.

Net open-market

+222K

1 buy · 4 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 3

executives and directors

Last open-market buy

Sep 2026

Sep 25, 2026

Get an email when DMRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 25	Jennifer Jarrett Director, President and CEO	Bought	12,500	$20.23	253K	2.5%	Form 4
Jul 6	Garrett Winslow General Counsel	SoldNo plan	245	$29.98	7K	9.7%	Form 4
Jan 2	Hans T. Schambye Chief Executive Officer	SoldNo plan	700	$21.38	15K	13%	Form 4
Jan 2	Garrett Winslow General Counsel	SoldNo plan	255	$21.38	5K	12%	Form 4
Jan 2	Lori Firmani Chief Financial Officer	SoldNo plan	135	$21.41	3K	13%	Form 4
Jul 3, 2025	Hans T. Schambye Chief Executive Officer	SoldNo plan	735	$3.38	2K	15%	Form 4
Jul 3, 2025	Garrett Winslow General Counsel	SoldNo plan	260	$3.39	$881	15%	Form 4
Jul 3, 2025	Lori Firmani Interim CFO	SoldNo plan	147	$3.39	$498	18%	Form 4
Jan 3, 2025	Garrett Winslow General Counsel	SoldNo plan	471	$5.60	3K	32%	Form 4
Jan 3, 2025	Lori Firmani Interim CFO	SoldNo plan	261	$5.63	1K	36%	Form 4
Jan 3, 2025	Hans T. Schambye Chief Executive Officer	SoldNo plan	1,341	$5.60	8K	28%	Form 4

Sep 25
Jennifer Jarrett
Director, President and CEO · bought 12,500 at $20.23
253K
2.5% of stake
Jul 6No plan
Garrett Winslow
General Counsel · sold 245 at $29.98
7K
9.7% of stake
Jan 2No plan
Hans T. Schambye
Chief Executive Officer · sold 700 at $21.38
15K
13% of stake
Jan 2No plan
Garrett Winslow
General Counsel · sold 255 at $21.38
5K
12% of stake
Jan 2No plan
Lori Firmani
Chief Financial Officer · sold 135 at $21.41
3K
13% of stake
Jul 3, 2025No plan
Hans T. Schambye
Chief Executive Officer · sold 735 at $3.38
2K
15% of stake
Jul 3, 2025No plan
Garrett Winslow
General Counsel · sold 260 at $3.39
$881
15% of stake
Jul 3, 2025No plan
Lori Firmani
Interim CFO · sold 147 at $3.39
$498
18% of stake
Jan 3, 2025No plan
Garrett Winslow
General Counsel · sold 471 at $5.60
3K
32% of stake
Jan 3, 2025No plan
Lori Firmani
Interim CFO · sold 261 at $5.63
1K
36% of stake
Jan 3, 2025No plan
Hans T. Schambye
Chief Executive Officer · sold 1,341 at $5.60
8K
28% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch DMRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with DMRA

CompareIntrinsic value

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

SCYXScynexis, Inc.

$3.84-2.54%40

HROWHarrow Inc.

$28.75+0.74%46

HRTXHeron Therapeutics Inc.

$0.30+7.14%36

RCKTRocket Pharmaceuticals Inc.

$2.61+3.98%10

BBIOBridgeBio Pharma, Inc.

$77.89+5.21%30

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

MRKMerck & Co., Inc.

$150.36+3.93%41

Held by ETFs

DMRA is in 23 US ETFs. The largest of them, with DMRA's weight in each:

Spot a number that looks wrong? Check it in DMRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing DMRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.